NasoShield Study of Safety and Immunogenicity
← catalyst calendarSponsored by Altimmune, Inc. (industry) · ALT — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Double · Prevention
Enrollment
145actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-31
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-01-18 | actual | When the study began enrolling |
| Primary completion | 2019-05-13 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2019-05-13 | actual | The whole study's end, after follow-up |
| First posted | 2017-11-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Biological: NasoShield
- Biological: BioThrax
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFReactogenicity
measured For 14 days after vaccination
Adverse events (AEs)
measured From Day 1 to Day 361
Related
ALT's other studiesmost recently updated first
- Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH Phase 3 · Recruiting
- RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) Phase 2 · Active, not recruiting
- RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight Phase 2 · Completed
- IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) Phase 2 · Completed
- HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB) Phase 2 · Terminated
Permalink · ALT's whole pipeline · Catalyst calendar · Every registered study · What changed